Render Target: STATIC
Render Timestamp: 2025-02-28T12:09:46.672Z
Commit: cb76efb1e1bf27d454180ac9a5e8c179c097b4c4
XML generation date: 2024-12-06 15:01:07.258
Product last modified at: 2025-02-20T18:00:10.812Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

Non-Homologous End Joining (NHEJ) DNA Repair Antibody Sampler Kit #76696

    Product Information

    Product Description

    The Non-Homologous End Joining (NHEJ) DNA Repair Antibody Sampler Kit provides an economical means of detecting proteins involved in NHEJ DNA repair. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Background

    DNA double-strand breaks (DSBs) are potentially hazardous lesions that can be induced by ionizing radiation (IR), radiomimetic chemicals, or DNA replication inhibitors. Cells recognize and repair DSBs via two distinct but partly overlapping signaling pathways, non-homologous end joining (NHEJ) and homologous recombination (HR). DNA repair via the HR pathway is restricted to S and G2 phases of the cell cycle, while NHEJ can occur during any phase. NHEJ machinery is also utilized in V(D)J recombination, a process that generates diversity in immunoglobulin and T cell receptor genes. Defects in both pathways have been associated with human disease, including cancer (1).
    DNA repair through the NHEJ pathway involves a core group of proteins that includes the Ku heterodimer (Ku70/Ku80), DNA-PKcs, DNA ligase IV, XRCC4, and XLF. XLF interacts with XRCC4 and promotes the ligation of DNA strands by DNA ligase IV and the ligase cofactor XRCC4. The ATP-dependent ligation of free DNA ends is the final step in the NHEJ repair pathway (2). DNA ligase IV and the endonuclease artemis suppress homologous recombination and promote NHEJ (3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.